The adipocyte-derived hormone leptin regulates appetite and bone mass. Recent research demonstrates that reciprocally, osteoblasts have a role in controlling energy metabolism. Several genes expressed in osteoblasts are involved in this process, and one of them is the Esp gene. The remaining genes regulate Esp gene expression. OST-PTP, the protein name of Esp, regulates the carboxylation of osteocalcin secreted from osteoblasts, thus affecting insulin sensitivity and insulin secretion. This review provides evidence for a novel interpretation of the connection between bone and energy metabolism and expands our understanding of the novel physiology of bone beyond its classical functions. [BMB reports 2010; 43(9): 579-583]
INTRODUCTION
Bone remodeling occurs in a constant and balanced manner in the body throughout adulthood. This process includes destruction of the mineralized bone matrix by osteoclasts and bone formation by osteoblasts (1, 2) . Considering that osteoporosis due to an increase in bone resorption (3) invariably follows gonadal failure (4) and obesity offers protection from osteoporosis (5, 6) , these observations suggest that body weight (or appetite), reproduction, and bone mass might be connected through the same hormone(s).
If this hypothesis is true, it implies that glucose and fat metabolism might be regulated by bone in a feedback loop. Indeed bone remodeling is a process requiring a considerable amount of energy (7), and breakage of energy homeostasis in the body hampers skeletal metabolism (8, 9) . By providing evidence supporting these hypotheses, recent mouse genetic studies and molecular approaches have enhanced our knowledge and understanding of the reciprocal regulation of bone and energy metabolism.
REGULATION OF BONE FORMATION BY LEPTIN
Leptin is a good candidate for investigating the existence of a common regulatory link between bone remodeling and energy metabolism. An adipocyte-derived hormone, leptin inhibits appetite and favors energy expenditure and fertility (10, 11) . Mice lacking either leptin (ob/ob) or its receptor (db/db) are obese and hypogonadal (12) .
Leptin-deficient ob/ob mice exhibit high bone mass due to a massive increase in bone formation parameters. This leptin-less animal model provides strong experimental evidence that leptin uses a central (presumably hypothalamic) relay to control bone mass because leptin treatment through intracerebroventricular (ICV) infusion in ob/ob mice fully corrects the bone phenotype caused by the leptin deficiency (13) . In addition, the infusion does not cause any detectable leak of leptin into the general circulation (10, 14) .
Two distinct mechanisms explain the regulation of bone resorption by leptin. Symphathetic signaling favors osteoclast differentiation by inducing the receptor activator of NF-kappaB ligand (Rankl), a true osteoclast differentiation factor (1), in osteoblasts. In contrast, leptin inhibits Rankl expression through the cocaine-and amphetamine-regulated transcript (CART) in the ventromeidal hypothalamus (VMH) (15) . Brain regulation of bone mass has been verified in other groups experimentally (10, (16) (17) (18) .
High bone mass of the ob/ob mice is a consequence of their lack of leptin -not obesity -because a Leptin transgene can correct the high bone mass of fat-free mice, which are lean and leptin-deficient because of the virtual absence of adipocytes (13) .
Together these studies suggest that leptin is the adipocytederived gene product responsible for the bone phenotype and is an important factor mediating functional connections between fat and bone.
didates is osteocalcin.
Osteocalcin, a low molecular weight (5,700 Da) protein produced by osteoblasts, is synthesized as a pre-promolecule with three glutamic acid residues (Glu) and is secreted into blood. Glutamic residues are gamma carboxylated during post-translational modifications into Gla residues by a vitamin K-dependent gamma carboxylase; hence, another name for osteocalcin is Bone Gla Protein (BGP) (19) (20) (21) .
Although until recently, no receptor has been reported for osteocalcin it demonstrates some features of a hormone. Primarily, it is cell-specific and secreted into blood. The observation that Osteocalcin -/-mice exhibited abnormally increased visceral fat (P. D. and G. K., unpublished data) also raises the possibility that osteocalcin may regulate energy metabolism. Moreover, in humans, when osteocalcin levels are decreased or osteocalcin is poorly carboxylated, the blood glucose level decreased in a manner similar to that shown in mice (22) (23) (24) .
Osteocalcin -/-mice have higher blood glucose levels and lower serum insulin levels than WT mice. Ki67 immunostaining showed that β-cell proliferation decreased in the pancreas of Osteocalcin -/-mice; however, fat mass increased in Osteocalcin -/-mice (25) . The bioactivity of osteocalcin is regulated by osteotesticular protein tyrosine phosphatase (OST-PTP), which has the gene name Esp (26) , and its expression is restricted to embryonic stem (ES) cells, Sertoli cells, and osteoblasts; it is not expressed in the pancreas or in fat (25, 27) . Esp -/-mice have a relative increase in uncarboxylated osteocalcin compared to the carboxylated form in the serum when hydroxyapatite beads are used; however, it failed to regulate osteocalcin expression (25) . A triple enzyme-linked immunosorbent assay (ELISA) system for quantification of mouse total, carboxylated, and uncarboxylated osteocalcin was developed, and it verified that carboxylation of osteocalcin decreased in the serum of Esp -/-mice (28) .
Esp-deficient mice display a metabolic phenotype that is the mirror image of the one present in the Osteocalcin-deficient mice; for example, a low blood glucose level and hyperinsulinemia compared to wild-type (WT) littermates. Since OST-PTP is a transmembrane protein and is not secreted (25, 27) , this implies that OST-PTP functions by regulating osteocalcin bioactivity. Indeed removing one allele of Osteocalcin from Esp -/-mice is sufficient to rescue the Esp -/-mice phenotype, which suggests that OST-PTP and osteocalcin are in the same regulatory pathway and Esp -/-mice are models of increased osteocalcin bioactivity (25) .
To verify whether uncarboxylated osteocalcin is the bioactive form that regulates energy metabolism, recombinant osteocalcin was produced bacterially; this yields an uncarboxylated form only because there is no expression of gamma carboxylase in bacteria. Its treatment induced the expression of insulin and cyclinD1, a cell cycle marker, in islets (25) . Osteocalcin pumps used to determine the direct effect of a 0.3 ng/h dose for 1 month demonstrated improved glucose handling (29) . It increased serum insulin levels, thus decreasing blood glucose levels in WT mice. An increase in β-cell proliferation and insulin expression was observed at low concentrations (0.3 ng/ml); however, insulin sensitivity and energy expenditure was exhibited at high concentrations (10 or 30 ng/ml). Although there is a difference in dose response (29) , these results support the role of osteocalcin in the regulation of energy metabolism.
Recently it was verified that expression of the Esp gene is regulated by ATF4 (30) favoring the expression of Rankl in osteoblasts, and by FoxO1 (31), a forkhead family transcription factor. Although Atf4 is a broadly expressed gene (32), Atf4 -/-mice. ATF4 is a known regulator of the expression of osteocalcin, and the metabolic phenotypes of Atf4 -/-mice are similar to that of Esp -/-mice, raising the possibility that ATF4 could regulate the expression of Esp, hampering the metabolic function of osteocalcin.
Analysis of the Esp promoter revealed the existence of cAMP-responsive element (CRE) at -340, and a sequence between -600 and -300 including the CRE of the Esp promoter is necessary for its activity. ChIP assays confirmed that ATF4 binds to the CRE element in the Esp promoter. These results indicate that ATF4 directly regulates Esp expression in osteoblasts. Likewise, the percentage of the bioactive form of osteoclacin decreased in the serum of α1(I)Collagen-Atf4 mice; however, it increased in Atf4osb -/-mice, even though the level of serum total osteocalcin decreased in Atf4osb -/-mice (30) . This genetic and molecular evidence strengthens the perspective that ATF4 achieves its function on metabolism through regulation of Esp expression.
In addition to ATF4, FoxO1 is another regulator of Esp gene expression. Since Esp, which is responsible for decreasing the bioactivity of osteocalcin. As expected, uncarboxylated osteocalcin increased in the serum of Foxo1osb -/-mice compared to that of WT mice (37) .
By showing that osteoblasts contribute to glucose homeostasis by controlling the expression of Esp and the bioactivity of osteocalcin this increasing body of evidence strongly suggests a tight link between bone and energy metabolism.
OSTEOBLAST-DEPENDENT LEPTIN REGULATION OF INSULIN SECRETION
Another factor enhancing Esp expression in osteoblasts is leptin (38) . In contrast to uncarboxylated osteocalcin, leptin plays a role in inhibiting insulin secretion, in part through a direct effect on β-cells (39) . This finding suggested the possibility that leptin may inhibit insulin secretion through indirect mechanisms to fulfill the function (e.g. via osteoblasts because it affects osteoblast functions) (40) .
Indeed, it was verified that leptin upregulates symphathetic tone, which favors Esp expression in osteoblasts. Using Leprsyn -/-mice (in which the leptin receptor is deleted in all neurons) researchers showed that leptin uses a neural pathway to regulate insulin secretion. In addition, a decrease in serum epinephrine, serum norepinephrine, and Ucp1 expression in brown fat was observed in these mice, reflecting a low sympathetic tone (38) . To investigate whether the sympathetic tone under the control of leptin regulates insulin secretion through osteoblasts,
Adrβ2osb
-/-mice (in which the adrenergic receptor is deleted only in osteoblasts) were generated (38) . As expected, Adrβ2osb -/-mice showed an increase in serum insulin levels. Long-term (1 wk) intracerebroventricular (ICV) infusion of leptin decreased glucose-stimulated insulin secretion in WT but not in Adrβ2osb -/-mice, supporting the idea that sympathetic signaling in osteoblasts contributes to leptin regulation of insulin secretion. In osteoblasts, isoproterenol, an agonist of the β-adrenergic receptor, upregulated Esp expression four-fold; however, the expression of osteocalcin did not change (41) . Accordingly, although the serum levels of total osteocalcin were normal, the amount of uncarboxylated osteocalcin increased in Adrβ2osb -/-mice. Studies using Adrβ2osb
+/-mice showed that ATF4 mediates the sympathetic regulation of insulin secretion through its expression in osteoblasts because serum insulin levels and β cell proliferation increased in these mice (41) . These results support the importance of the crosstalk existing between adipocytes and osteoblasts for the regulation of glucose homeostasis (Fig. 1) .
CONCLUSION
Recently, mouse genetic experiments and molecular results uncovered novel physiology of the skeleton, highlighting a link between bone and glucose metabolism. A similar relationship is true in humans. Growing clinical evidence supports the relationship between osteocalcin and glucose levels; for example, abnormal levels of osteocalcin (or its carboxylation ratio in serum) reflect changes in glucose metabolism (42) (43) (44) . Although a specific receptor for osteocalcin has not been identified, these observations demonstrate that bone performs completely different roles as an endocrine organ, by showing how integrative and tremendous skeleton physiology is. This insight into bone physiology leads us to investigate the skeletal system for therapeutic targets of type II diabetes as well as osteoporosis.
